title: Local Oestrogen for Pelvic Floor Disorders: A Systematic Review.
abstract: OBJECTIVE
  The decline in available oestrogen after menopause is a possible etiological factor in pelvic floor disorders like vaginal atrophy (VA), urinary incontinence (UI), overactive bladder (OAB) and pelvic organ prolapse (POP). This systematic review will examine the evidence for local oestrogen therapy in the treatment of these pelvic floor disorders.
  
  
  METHODS
  We performed a systematic search in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and the non-MEDLINE subset of PubMed from inception to May 2014. We searched for local oestrogens and VA (I), UI/OAB (II) and POP (III). Part I was combined with broad methodological filters for randomized controlled trials (RCTs) and secondary evidence. For part I and II two reviewers independently selected RCTs evaluating the effect of topical oestrogens on symptoms and signs of VA and UI/OAB. In part III all studies of topical oestrogen therapy in the treatment of POP were selected. Data extraction and the assessment of risk of bias using the Cochrane Risk of Bias Tool was undertaken independently by two reviewers.
  
  
  RESULTS
  The included studies varied in ways of topical application, types of oestrogen, dosage and treatment durations. Objective and subjective outcomes were assessed by a variety of measures. Overall, subjective and urodynamic outcomes, vaginal maturation and vaginal pH changed in favor of vaginal oestrogens compared to placebo. No obvious differences between different application methods were revealed. Low doses already seemed to have a beneficial effect. Studies evaluating the effect of topical oestrogen in women with POP are scarce and mainly assessed symptoms and signs associated with VA instead of POP symptoms.
  
  
  CONCLUSIONS
  Topical oestrogen administration is effective for the treatment of VA and seems to decrease complaints of OAB and UI. The potential for local oestrogens in the prevention as well as treatment of POP needs further research.
authors.affiliation: Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: M A
authors.initials: MA
authors.lastname: Weber
authors.affiliation: Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: M H
authors.initials: MH
authors.lastname: Kleijn
authors.affiliation: Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Langendam
authors.affiliation: Medical Library, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Limpens
authors.affiliation: Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Heineman
authors.affiliation: Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: J P
authors.initials: JP
authors.lastname: Roovers
mesh_terms: D000287:Administration, Topical; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D059952:Pelvic Floor Disorders / Q000188:drug therapy*; D056887:Pelvic Organ Prolapse / Q000188:drug therapy*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*
chemical_list: D004967:Estrogens